On Monday, the same day the GAVI Alliance helped oversee the roll out of a routine pneumococcal vaccine in Kenya, GAVI chairman Dagfinn Hoybraten highlighted the need for greater reductions in vaccine prices in developing countries during an interview with Reuters, the news service reports. The piece examines the funding mechanism in place to finance the pneumococcal vaccines, known as Advance Market Commitment (AMC), as well as the budget shortfall facing the group (Kelland, 2/14).
Private Sector Involvement
“A rise in global funding for research into neglected diseases needs to be matched by a continued focus on delivering practical new ways to curb sickness in the developing world,” according to the third annual report by the Global Funding of Innovation for Neglected Diseases (G-FINDER) released on Wednesday, Reuters reports.
Factors Contributing to HealthÂ Of Women Worldwide: The Kaiser Family Foundation features a narrated slide tutorial by epidemiologist Laurel Spielberg on the health issues facing women around the world. The tutorial touches on issues such as economic status and biological, social, and cultural factors that affect women’s health, as well as…
New Strategies To Improve Developing Countries’ Access To Low-Cost Generic Drugs Needed, Experts Say
New strategies that ensure developing countries have access to low-cost generic medicines and encourage innovation are needed, according to experts who attended a recent meeting sponsored by the WHO, World Intellectual Property Organization, and World Trade Organization (WTO) that addressed growing concern that strict intellectual property protections are limiting access to low-cost generic medicines, BMJ News reports.
The U.N. on Friday said Haiti’s cholera outbreak appears to be waning overall, but high death rates from the virus in rural regions of the country remain a concern, the Associated Press reports. According to figures released by the Haitian government, 231,070 cholera cases and 4,549 deaths from the disease have been reported since the outbreak first emerged in October.
New Resources On Federal Global Health, HIV/AIDS Budgets: The Kaiser Family Foundation has released a collection of new resources examining global health and HIV/AIDS funding in the Obama administration’s FY12 budget proposal. A new fact sheetÂ breaks down the $9.8 billion budget request for the Global Health Initiative (GHI), a six-year,…
Star-Ledger Examines Tibotec’s Agreement With Generic Drug Makers On Experimental HIV/AIDS Treatment
In a piece on the move by drug manufacturer Tibotec Pharmaceuticals to grant licenses to generic manufacturers in India and South Africa to create copies of its experimental HIV/AIDS drug, the New Jersey Star-Ledger examines why drug companies are particularly focused on expanding their reach in sub-Saharan Africa.
The U.K.’s Department for International Development (DFID) on Saturday said it might reduce its contribution to the U.N. Food and Agriculture Organization (FAO) if the agency does not improve its performance, Reuters reports. According to a DFID review, “FAO’s performance is patchy, particularly at country level, and that reforms need to be prioritised.”
Also In Global Health News: Libyan Refugee Crisis; HIV Vaccine Program In India; Speeding Drug Development; Ugandan Malaria Training Program
As Thousands Flee Libya, World Leaders, International Aid Agencies Respond With Humanitarian Aid “Libyan border crossings were overwhelmed Wednesday by tens of thousands of hungry, fearful people fleeing its burgeoning civil war,” the Associated Press reports. “U.S. Ambassador Betty King in Geneva said the United States is giving $12 million…
President’s Bioethics Commission Names International Panel To Review Whether U.S. Rules Protect Clinical Trial Participants In U.S., Abroad
“Prompted by concerns about an unethical U.S.-sponsored study in the 1940s,” the Presidential Commission for the Study of Bioethical Issues on Tuesday announced the formation of an international panel “that will examine whether current rules adequately protect volunteers in global clinical trials,” Science’s “ScienceInsider” blog reports (Kaiser, 3/1).